Evidence map›Paper›PMID 31496103›Full record

ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2019

The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials.

Joseph Firth, Scott B Teasdale, Kelly Allott, Dan Siskind, Wolfgang Marx, Jack Cotter, Nicola Veronese, Felipe Schuch, Lee Smith, Marco Solmi and 5 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04844034 (The Effects of a High Eicosapentaenoic Acid Multinutrient Supplement on Measures of Stress, Anxiety and Depression in Young Adults), which is not on this map. Cited by 94 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 13 pooled it
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04844034 naunknown statusnot on this mapstarted 2022, after this paper: background citation

The Effects of a High Eicosapentaenoic Acid Multinutrient Supplement on Measures of Stress, Anxiety and Depression in Young Adults: a Randomised, Double-blind, Placebo-controlled Trial.

TypeinterventionalSponsorUniversity of RoehamptonRan2022 to 2023Enrolled94ConditionsAnxiety, DepressionArmsHigh-EPA multinutrient supplement., Placebo
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 13 syntheses or guidelines pooled it, 202 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Omega-3 fatty acids for depression in adults.The Cochrane database of systematic reviews · 2021
    Pooled it
  9. The efficacy and safety of bisphosphonate analogs for treatment of osteoporosis after spinal cord injury: a systematic review and meta-analysis of randomized controlled trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 14 institutions in 6 countries.

Joseph FirthNICM Health Research Institute, Western Sydney University, Westmead, Australia.
Scott B TeasdaleSchool of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia.
Kelly AllottCentre for Youth Mental Health, University of Melbourne, Melbourne, Australia.
Dan SiskindMetro South Addiction and Mental Health Service, Brisbane, Australia.
Wolfgang MarxIMPACT Strategic Research Centre, School of Medicine, Deakin University, Barwon Health, Australia.
Jack CotterCambridge Cognition, Cambridge, UK.
Nicola VeroneseNeuroscience Institute, National Research Council, Padua, Italy.
Felipe SchuchDepartment of Sports Methods and Techniques, Federal University of Santa Maria, Santa Maria, Brazil.
Lee SmithCambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK.
Marco SolmiDepartment of Neurosciences, University of Padua, Padua, Italy.
André F CarvalhoCentre for Addiction and Mental Health, Toronto, ON, Canada.
Davy VancampfortKU Leuven Department of Rehabilitation Sciences, Leuven, Belgium.
Michael BerkOrygen, The National Centre of Excellence in Youth Mental Health, Parkville, Australia.
Brendon StubbsSouth London and Maudsley NHS Foundation Trust, London, UK.
Jerome SarrisNICM Health Research Institute, Western Sydney University, Westmead, Australia.
Barwon Health · AUAnglia Ruskin University · GBCambridge Cognition (United Kingdom) · GBCentre for Addiction and Mental Health · CAGastroenterology Hospital "Saverio de Bellis" · ITKing's College London · GBKU Leuven · BEMelbourne Clinic · AUSouth Eastern Sydney Local Health District · AUThe University of Melbourne · AUThe University of Queensland · AUUniversidade Federal de Santa Maria · BRUniversity of Padua · ITWestmead Institute · AU

Funding

Department of Health ICA-CL-2017-03-001
6 · The paper itself

Abstract

The role of nutrition in mental health is becoming increasingly acknowledged. Along with dietary intake, nutrition can also be obtained from "nutrient supplements", such as polyunsaturated fatty acids (PUFAs), vitamins, minerals, antioxidants, amino acids and pre/probiotic supplements. Recently, a large number of meta-analyses have emerged examining nutrient supplements in the treatment of mental disorders. To produce a meta-review of this top-tier evidence, we identified, synthesized and appraised all meta-analyses of randomized controlled trials (RCTs) reporting on the efficacy and safety of nutrient supplements in common and severe mental disorders. Our systematic search identified 33 meta-analyses of placebo-controlled RCTs, with primary analyses including outcome data from 10,951 individuals. The strongest evidence was found for PUFAs (particularly as eicosapentaenoic acid) as an adjunctive treatment for depression. More nascent evidence suggested that PUFAs may also be beneficial for attention-deficit/hyperactivity disorder, whereas there was no evidence for schizophrenia. Folate-based supplements were widely researched as adjunctive treatments for depression and schizophrenia, with positive effects from RCTs of high-dose methylfolate in major depressive disorder. There was emergent evidence for N-acetylcysteine as a useful adjunctive treatment in mood disorders and schizophrenia. All nutrient supplements had good safety profiles, with no evidence of serious adverse effects or contraindications with psychiatric medications. In conclusion, clinicians should be informed of the nutrient supplements with established efficacy for certain conditions (such as eicosapentaenoic acid in depression), but also made aware of those currently lacking evidentiary support. Future research should aim to determine which individuals may benefit most from evidence-based supplements, to further elucidate the underlying mechanisms.

Indexed as

adjunctive treatmentattention-deficit/hyperactivity disorderdepressioneicosapentaenoic acidmethylfolateN-acetylcysteineNutrient supplementsomega-3polyunsaturated fatty acidsschizophreniavitamin D

Identifiers

PMID31496103
PMCPMC6732706
OpenAlexW2971872318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.